

**ondine**



**For Immediate Release**

**Data Demonstrating Efficacy of Periowave™ Photodisinfection Therapy for the Treatment of Gum Disease Presented at 12<sup>th</sup> Congress of the European Society of Photobiology**

*-- Presentation by Professor Michael Wilson highlights success of Ondine's clinical trials --*

**Vancouver, Canada – September 19, 2007** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company, announces that Professor Michael Wilson presented data demonstrating the efficacy of photodisinfection therapy for the treatment of gum disease at the 12<sup>th</sup> Congress of the European Society of Photobiology on September 4<sup>th</sup>, 2007 in Bath, UK. In his presentation to the European scientific community titled “Light-activated antimicrobial agents for the treatment of periodontitis” Professor Wilson discussed the efficacy of the photodisinfection by highlighting his substantial pre-clinical research spanning 20 years and Ondine’s positive clinical results utilizing its Periowave Photodisinfection System.

Michael Wilson (GRSC, MSc, PhD, DSc, FRCPath) is a Professor of Microbiology at the Eastman Dental Institute at University College London (UCL) and Honorary Principal Bacteriologist at the Eastman Dental Hospital. He is also Editor of the journal, *Biofilms*, and is a world renowned pioneer in the development of photodisinfection technologies. Professor Wilson has published more than 250 original research papers, over 200 scientific research abstracts relating to antibiotic resistance, biofilms, bacterial virulence factors, and the development of new antimicrobial strategies and co-authored four books.

“It is extremely exciting that a company like Ondine is advancing clinical work in this field,” stated Professor Wilson. “It is gratifying to see the years of preclinical work that we undertook at UCL evolve into a successful therapy for such a pervasive disease.”

**About Periowave™ and Photodisinfection**

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated photosensitive compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are topically applied and lasers of appropriate wavelength and intensity are used to disinfect the treatment site. The Photodynamic Disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica plc, University College London. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com).

## **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com)

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

*The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release*

### **For further information please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
[ccross@ondinebiopharma.com](mailto:ccross@ondinebiopharma.com)

Christina Bessant  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
[cbessant@equicomgroup.com](mailto:cbessant@equicomgroup.com)

Irma Gomez-Dib  
US Media Relations  
FD  
(212) 850 5600  
[Irma.gomez.dib@fd.com](mailto:Irma.gomez.dib@fd.com)

Nominated Adviser  
Neil Johnson /  
Ryan Gaffney  
Canaccord Adams Ltd  
+44(0)20 7050 6500